BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo

BMC Complementary and Alternative Medicine

Research Article

Isaac Eliaz¹  Victor Castillo²  Mark Alvarado²  Matt Welty²  Daniel Sliva³  Shujie Cheng⁴  George E. Sandusky⁵  Constance J. Temm⁵ 

[1] Amitabha Medical Clinic and Healing Center, 95401, Santa Rosa, CA, USA;Cancer Research Laboratory, Methodist Research Institute, Indiana University Health, 46202, Indianapolis, IN, USA;Cancer Research Laboratory, Methodist Research Institute, Indiana University Health, 46202, Indianapolis, IN, USA;Department of Medicine, Indiana University School of Medicine, 46202, Indianapolis, IN, USA;DSTest Laboratories, Purdue Research Park, 5225 Exploration Drive, 46241, Indianapolis, IN, USA;Cancer Research Laboratory, Methodist Research Institute, Indiana University Health, 46202, Indianapolis, IN, USA;Present address: Department of Food Quality and Safety, School of Engineering, China Pharmaceutical University, Nanjing, People’s Republic of China;Department of Pathology, Indiana University School of Medicine, 46202, Indianapolis, IN, USA;

关键词: Polybotanical supplement;    BreastDefend;    Tamoxifen;    Estrogen receptor;    MCF-7;    Xenograft model;    Apoptosis;   

DOI  :  10.1186/s12906-017-1621-7

 received in 2016-08-22, accepted in 2017-02-02,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundTamoxifen (TAM) has been widely used for the treatment of estrogen receptor (ER)-positive breast cancer and its combination with other therapies is being actively investigated as a way to increase efficacy and decrease side effects. Here, we evaluate the therapeutic potential of co-treatment with TAM and BreastDefend (BD), a dietary supplement formula, in ER-positive human breast cancer.MethodsCell proliferation and apoptosis were determined in ER-positive human breast cancer cells MCF-7 by MTT assay, quantitation of cytoplasmic histone-associated DNA fragments and expression of cleaved PARP, respectively. The molecular mechanism was identified using RNA microarray analysis and western blotting. Tumor tissues from xenograft mouse model were analyzed by immunohistochemistry.ResultsOur data clearly demonstrate that a combination of 4-hydroxytamoxifen (4-OHT) with BD lead to profound inhibition of cell proliferation and induction of apoptosis in MCF-7 cells. This effect is consistent with the regulation of apoptotic and TAM resistant genes at the transcription and translation levels. Importantly, TAM and BD co-treatment significantly enhanced apoptosis, suppressed tumor growth and reduced tumor weight in a xenograft model of human ER-positive breast cancer.ConclusionBD sensitized ER-positive human breast cancer cells to 4-OHT/TAM treatment in vitro and in vivo. BreastDefend can be used in an adjuvant therapy to increase the therapeutic effect of tamoxifen in patients with ER-positive breast cancer.

【 授权许可】

CC BY   
© The Author(s). 2017